Fig. 5.
Administration of AT132 can effectively suppress the development of arthritis in TgTC mice. Sections of the knee joint at 8 weeks of age: wild-type mice (A), TgTC mice treated by saline weekly (B) and TgTC mice treated by AT132 at 1.25 mg/kg weekly (C) are shown. Thickening of the synovial layer (arrow) is completely suppressed in the antibody-treated transgenic mice. Treatment by AT132 at 1.25 mg/kg weekly can inhibit hTNFα production in synovial tissue of TgTC mice (D) (TgTC, 5635±585.7 pg/g; TgTC+AT132 1.25 mg/kg, 151.6±14.92 pg/g). Data presented as mean±s.e.m. Asterisk indicates a significant difference between saline- and AT132-treated samples. ***P<0.001 (t-test), Scale bars=200 μm.